Home/Filings/4/0000950170-24-129830
4//SEC Filing

Readnour Robin Shane 4

Accession 0000950170-24-129830

CIK 0001880438other

Filed

Nov 20, 7:00 PM ET

Accepted

Nov 21, 6:00 PM ET

Size

11.2 KB

Accession

0000950170-24-129830

Insider Transaction Report

Form 4
Period: 2024-11-19
Transactions
  • Purchase

    Common Stock

    2024-11-19$1.04/sh+75,000$77,730489,788 total(indirect: See Footnote)
  • Purchase

    Common Stock

    2024-11-20$1.16/sh+25,000$29,000585,073 total(indirect: See Footnote)
  • Purchase

    Common Stock

    2024-11-19$1.03/sh+75,000$77,528560,073 total(indirect: See Footnote)
  • Purchase

    Common Stock

    2024-11-20$1.15/sh+25,000$28,870514,788 total(indirect: See Footnote)
Footnotes (5)
  • [F1]This price represents the weighted average purchase price for multiple transactions reported on this line. The prices of the transactions reported on this line ranged from $1.0211 to $1.05. Upon request by the Commission staff, the issuer or a security holder of the issuer, the reporting person will undertake to provide full information regarding the number of shares sold at each separate price.
  • [F2]MGC Venture Partners 2018 GP, LLC ("MGC 2018 GP") is the general partner of MGC Venture Partners 2018, LP ("MGC 2018 LP") and MGC Venture Partners QP 2018 LP ("MGC 2018 QP"). MGC 2018 GP has shared voting and shared dispositive power over the shares held by MGC 2018 LP and MGC 2018 QP. The Reporting Person is a member of the Issuer's board of directors and is a member of MGC 2018 QP and MGC 2018 LP and a managing partner of MGC 2018 GP and has shared voting power and shared dispositive power over the shares of common stock held by MGC 2018 LP and MGC 2018 QP. The Reporting Person disclaims beneficial ownership of the securities, except to the extent of such person's pecuniary interest in such securities.
  • [F3]Shares held directly by MGC 2018 QP.
  • [F4]This price represents the weighted average purchase price for multiple transactions reported on this line. The prices of the transactions reported on this line ranged from $1.0293 to $1.05. Upon request by the Commission staff, the issuer or a security holder of the issuer, the reporting person will undertake to provide full information regarding the number of shares sold at each separate price.
  • [F5]Shares held directly by MGC 2018 LP.

Documents

1 file

Issuer

AN2 Therapeutics, Inc.

CIK 0001880438

Entity typeother

Related Parties

1
  • filerCIK 0001914883

Filing Metadata

Form type
4
Filed
Nov 20, 7:00 PM ET
Accepted
Nov 21, 6:00 PM ET
Size
11.2 KB